

Report Information

More information from: <https://www.marketresearchfuture.com/reports/carcinoembryonic-antigen-market-772>



Carcinoembryonic Antigen Market Research Report - Global Forecast till 2032

Report / Search Code: MRFR/Pharma/0288-HCR Publish Date: April, 2024

Request Sample

Price	1-user PDF : \$ 4950.0	Site PDF : \$ 5950.0	Enterprise PDF : \$ 7250.0
-------	------------------------	----------------------	----------------------------

Description:

Global Carcinoembryonic Antigen Market Overview

Carcinoembryonic Antigen Market Size was valued at USD 1.1 Billion in 2022. The Carcinoembryonic Antigen market industry is projected to grow from USD 1.26 Billion in 2023 to USD 3.93 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 15.2% during the forecast period (2023 - 2032).Cancer is becoming more common, increasing healthcare costs and making diagnostic technologies the key market drivers contributing to market growth and expansion.

Carcinoembryonic Antigen Market

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Cancer is the second leading cause of death worldwide, and over 70% of cancer fatalities occur in non-urban settings. The rising rate of new cancer diagnoses each year is a key factor fueling the expansion of this market, as is the rising cost of healthcare per person. The use of tobacco products and excessive alcohol consumption is the single most important preventable cause of cancer and is responsible for about 22 percent of all cancer deaths. This has created a market demand for CEA testing.

Demand for carcinoembryonic antigen tests is predicted to rise over the projection period, in part due to the launch and ongoing development of innovative immunological techniques such the radioimmunoassay. Over the projection period, innovative biomarkers that may be utilized in combination with other biomarkers are expected to play a significant role in driving market expansion.

Market expansion is being spurred on by factors including the rising prevalence of chronic diseases among the elderly, advances in technology, and government programs aimed at raising cancer awareness, such as those launched by the non-profit Cancer Prevention and Control Research Network (CPCRN). When it comes to identifying recurrent diseases that may be treatable, CEA seems to be the most cost-effective test. Companies are merging and buying one other up because of how concentrated the market is. To remain competitive, manufacturers must constantly innovate and respond to consumer demands.

April 2023, researchers have identified new biomarkers that can predict patients' likelihood of relapse after surgery for colorectal cancer. The Shanghai Cancer Center recommends using only cheap and painless blood tests for checking biomarkers. The function of ctDNA in the onset, progression, and recurrence of colorectal cancer has been extensively studied. According to the study's findings, a ctDNA methylation test is 20 months ahead of an imaging test in detecting relapse and is more sensitive in predicting relapse risk than the commonly used carcinoembryonic antigen (CEA). The field of clinical us has tremendous potential.

Carcinoembryonic Antigen Market Trends

- The growing healthcare costs are driving the market growth

Rising healthcare costs are driving Market CAGR for carcinoembryonic antigen. Rising cancer prevalence and increased awareness are key CEA factors and trends fueling the market to expand. Rise in cancer patients due to mortality worldwide, accounting for around 70% of all fatalities. Every year, the number of patients with cancer reports increases, resulting in increased per capita healthcare spending and minimally diagnostic treatments, which pushes market expansion higher. Tobacco and alcohol consumption is the greatest risk factor for cancer, accounting for around 22% of cancer deaths. This leads to an increase in the number of CEA tests available in the cancer-related embryonic antigen field. Rise in the elderly population: older people are more susceptible to technological innovation and chronic illness conditions, and government cancer education campaigns by NGOs such as Tumor Control and Prevention Study Network are driving the market growth. CEA seems to be the least expensive test for detecting treatable recurrent illness.

Additionally, there is a high risk of infection while doing various examinations, which can develop into cancer if the individual in question is a senior adult with a weakened immune system. This has the potential to be a significant market opportunity. The rising prevalence of cancer is being attributed to reasons such as increased intake of alcohol, processed foods, and desk-bound lives, which presents an opportunity for the Carcinoembryonic Antigen Market. Continuous advancement and development of innovative immunological techniques will likely create new economic possibilities, expanding the market. Other potential includes the discovery of new biomarkers and an increase in per-capita healthcare spending. As a result, the market has a lot of room to develop.

Pharmaceutical and biotech businesses collaborate with governments worldwide to combat the COVID-19 epidemic, from vaccine research to planning for drug supply chain issues. Approximately 115 vaccine candidates, including 155 compounds, are now in the R&D pipeline. Furthermore, routinely used medications which include

hydroxychloroquine, have experienced a huge increase in demand for COVID-19 control. As many affluent nations face a scarcity of these medications, the increased demand for COVID-19 management therapies has created enormous business potential. The demand for vaccines and treatment medications in the biotechnology and pharmaceutical sectors is predicted to increase significantly. This, in turn, is predicted to have a substantial influence.

For instance, according to WHO estimates, the cancer incidence (cases per year) in 2012 was roughly 14.1 million, with 7.4M males and 6.7M female patients. According to the Age-Standardized (AS) incidence rate, there are almost 205 instances of new cancer for every 100,000 men and 165 for every 100,000 women. Thus, demand for Carcinoembryonic Antigen is anticipated to increase throughout the projected timeframe due to the rising healthcare costs. Thus, driving the Carcinoembryonic Antigen market revenue.

Carcinoembryonic Antigen Market Segment Insights

Carcinoembryonic Antigen Application Insights

The Carcinoembryonic Antigen market segmentation, based on Application, includes Colorectal Cancer, Pancreatic Cancer, Breast Cancer, Lung Cancer, and Others. The colorectal cancer segment dominated the market, accounting for 35% of market revenue (USD 0.4 billion) in 2022. Because of the increased prevalence of colorectal cancer, in addition to using the CEA test at each stage of the illness, colorectal cancer is predicted to be one of the most lucrative revenue-generating segments.

Carcinoembryonic Antigen End-User Insights

The Carcinoembryonic Antigen market segmentation, based on End-Users, includes Hospitals and Clinics, Diagnostic Centers, and Others. The hospitals and clinics category Informatics category generated the highest market revenue of about 51% (USD 0.6 billion) in 2022. The rising prevalence of cancer worldwide accounts for the biggest proportion of hospitals, and tests carried out in hospitals have advantages, including being connected to medical facilities via IoT and enhanced diagnosis precision as all necessary information about patients boosts market growth.

Figure 1: Carcinoembryonic Antigen Market by End-User, 2022 & 2032 (USD Billion)

Carcinoembryonic Antigen Market by End-User, 2022 & 2032

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

June 2023: A unique CAR T cell method utilizing logic-gating is now being trialed for the treatment of solid tumors at NYU Langone Health's Perlmutter Cancer Center, with results expected in June 2023. Phase 1/2 of the EVEREST-1 trial's first patient was enrolled at Perlmutter Cancer Center. A2B530 is an autologous logic-gated Tmod CAR T-cell product developed to address a significant challenge in the treatment of solid tumors: how to selectively target the tumor while avoiding normal tissue. Cancers of the pancreas, colon, and lungs share a similar tumor marker called carcinoembryonic antigen (CEA), which is the focus of A2B530. Conversely, CEA can be found in normal tissues as well.

April 2023: Clinical trials of the innovative Tri-Ad5 vaccination combination and the IL-15 superagonist N-803 for persons with the inherited disorder Lynch syndrome were announced

Carcinoembryonic Antigen Regional Insights

By region, the research provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American Carcinoembryonic Antigen market area will dominate this market during the projected timeframe owing to the increased incidence and prevalence of various malignancies between older and middle-aged demographics are important market drivers which will boost the market growth in the North American region.

Further, the major countries studied in the market report are the US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: Carcinoembryonic Antigen Market Share by Region 2022 (USD Billion)

Carcinoembryonic Antigen Market Share by Region 2022

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Europe region's Carcinoembryonic Antigen market accounts for the second-highest market share due to the Untapped prospects, continually improved healthcare facilities growth in the economy, and more patient awareness are some of the elements driving this rapid expansion. Further, the German Carcinoembryonic Antigen market holds the largest market share, and the UK Carcinoembryonic Antigen market is expected to grow and expand significantly in the European region during the projected timeframe.

The Asia-Pacific Carcinoembryonic Antigen Market is expected to grow quickly during the projected timeframe. Growing cancer prevalence, an aging population, sufficient facilities for institutions and diagnostic centers, and greater aging population awareness of cancer treatment. Moreover, China's Carcinoembryonic Antigen market dominates the market share, and the Indian Carcinoembryonic Antigen market is expected to expand and grow steadily in the Asia-Pacific region during the projected timeframe.

Carcinoembryonic Antigen Key Market Players & Competitive Insights

Leading market players invested heavily in research and Development (R&D) to scale up their manufacturing units and develop technologically advanced solutions, which will help the Carcinoembryonic Antigen market grow worldwide. Market participants are also undertaking various organic or inorganic strategic approaches to strengthen and expand their footprint, with significant market developments including new product portfolios, contractual deals, mergers and acquisitions, capital expenditure, higher investments, and strategic alliances with other organizations. Businesses are also coming up with marketing strategies such as digital marketing, social media influencing, and content marketing to increase their scope of profit earnings. The Carcinoembryonic Antigen industry must offer cost-effective and sustainable options to survive in a highly fragmented and dynamic market climate.

Manufacturing locally to minimize operational expenses and offer aftermarket services to customers is one of the critical business strategies organizations use in the Carcinoembryonic Antigen industry to benefit customers and capture untapped market share and revenue. The Carcinoembryonic Antigen industry has recently offered significant

advantages to the medicine and pharmaceutical industry. Moreover, more industry participants are utilizing and adopting cutting-edge Technology has grown substantially. Major players in the Carcinoembryonic Antigen market, including Lee BioSolutions, F. Hoffmann-La Roche, Quest Diagnostics, Genway Biotech, RayBiotech, Merck KGaA, Abcam plc, Boster Biological Technology, Creative Diagnostics, and Laboratory Corporation of America Holdings and others are attempting to expand market share and demand by investing in R&D operations to produce sustainable and affordable solutions.

Kitov Pharmaceuticals Ltd. is a pharmaceutical development company. The organization concentrates on developing and marketing pharmacological solutions for managing hypertension and osteoarthritis pain. Kitov Pharmaceuticals is based in Israel. Kitov Pharma created the first-in-class combination cancer medicines in April 2019

Redpath is a molecular diagnostics laboratory in Pittsburgh focusing on bringing unique solutions to doctors. Their unique PathFinderTG® technology generates mutational profiles to assist clinicians in resolving complicated diagnostic quandaries in cancer-risk patients. Redpath conducts all clinical research and testing in its cutting-edge, CLIA-certified, & CAP-accredited lab. Redpath Integrated Pathology introduced a novel, patent-pending customized test in 2019 to accurately assess CEA across all pancreas cyst fluids. Because the market is so robust, corporations are pursuing mergers and acquisitions. Manufacturers are under constant pressure to put new technologies into the market with greater sensitivity.

Key Companies in the Carcinoembryonic Antigen market include

- Lee BioSolutions
- F. Hoffmann-La Roche
- Quest Diagnostics Incorporated
- Genway Biotech
- RayBiotech
- Merck KGaA
- Abcam plc
- Boster Biological Technology
- Creative Diagnostics
- Laboratory Corporation of America Holdings

Carcinoembryonic Antigen Industry Developments

April 2019:Kitov Pharma created the first-in-class combination cancer medicines in April 2019.

2019:Redpath Integrated Pathology introduced a new, patent-pending customized test 2019 to assess CEA across all pancreas cyst fluids accurately. Because the market is so robust, corporations are pursuing mergers and acquisitions. Manufacturers are under constant pressure to put new technologies into the market with greater sensitivity.

Carcinoembryonic antigen, in conjunction with the mucin tumor markers CA19-9, and CA242, can be utilized in preoperative staging, assisting in planning the kind of surgery necessary and future therapy choices. The rapidly growing older population, predisposed to chronic medical diseases such as cancer, is expected to broaden the customer base. Technological breakthroughs in proteomics, including mass spectrometry, protein labeling, array-based techniques, images, and molecular bioinformatics, have enabled researchers to quickly uncover and comprehend new biomarkers.

Carcinoembryonic Antigen Market Segmentation

Carcinoembryonic Antigen Application Outlook

- Colorectal Cancer
- Pancreatic Cancer

- Breast Cancer
- Lung Cancer
- Others

Carcinoembryonic Antigen End-User Outlook

- Hospitals and Clinics
- Diagnostic Centers
- Others

Carcinoembryonic Antigen Regional Outlook

- North America
 - US
 - Canada
- Europe
 - Germany
 - France
 - UK
 - Italy
 - Spain
 - Rest of Europe
- Asia-Pacific
 - China
 -

- Japan
 - India
 - Australia
 - South Korea
 - Australia
 - Rest of Asia-Pacific
- Rest of the World
 - Middle East
 - Africa
 - *Latin America*

Table of Content:

Contents

TABLE OF CONTENTS

1. REPORT PROLOGUE

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Primary Research

3.3. Secondary Research

3.4. Market Size Estimation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter's Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

5.2.1. R&D and Designing

5.2.2. Manufacturing

5.2.3. Distribution & Sales

5.2.4. Post Sales Services

6. GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET, BY APPLICATION

6.1. Overview

6.2. Colorectal Cancer

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3. Pancreatic Cancer

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4. Breast Cancer

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.5. Lung Cancer

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.6. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7. GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET, BY END USER

7.1. Overview

7.2. Hospitals and Clinics

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3. Diagnostic Centers

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.4. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8. GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET, BY REGION

8.1. Overview

8.2. Americas

8.2.1. North America

8.2.1.1. US

8.2.1.2. Canada

8.2.2. Latin America

8.3. Europe

8.3.1. Western Europe

8.3.1.1. Germany

8.3.1.2. France

8.3.1.3. Italy

8.3.1.4. Spain

8.3.1.5. UK

8.3.1.6. Rest of Western Europe

8.3.2. Eastern Europe

8.4. Asia-Pacific

8.4.1. Japan

8.4.2. China

8.4.3. India

8.4.4. Australia

8.4.5. South Korea

8.4.6. Rest of Asia-Pacific

8.5. Middle East & Africa

8.5.1. Middle East

8.5.2. Africa

9. COMPANY LANDSCAPE

9.1. Overview

9.2. Competitive Analysis

9.3. Market Share Analysis

9.4. Major Growth Strategy in the Global Carcinoembryonic Antigen Market

9.5. Competitive Benchmarking

9.6. Leading Players in Terms of Number of Developments in the Global Carcinoembryonic Antigen Market

9.7. Key Developments and Growth Strategies

9.7.1. New Product Launches

9.7.2. Mergers and Acquisitions

9.7.3. Joint Ventures

9.8. Major Players Financial Matrix & Market Ratio

9.8.1. Sales & Operating Income 2020

9.8.2. Major Players R&D Expenditure 2020

9.9. Major Players Capital Market Ratio

10. COMPANY PROFILES

10.1. Abcam plc

10.1.1. Company Overview

10.1.2. Product Overview

10.1.3. Financial Overview

10.1.4. Key Developments

10.1.5. SWOT Analysis

10.1.6. Key Strategies

10.2. Boster Biological Technology

10.3. Creative Diagnostics

10.4. F. Hoffmann-La Roche Ltd

10.5. Genway Biotech, Inc.

10.6. Laboratory Corporation of America Holdings

10.7. Lee BioSolutions

10.8. Merck KGaA

10.9. Quest Diagnostics Incorporated

10.10. RayBiotech, Inc.

10.11. Others

11. APPENDIX

11.1. References

11.2. Related Reports

LIST OF TABLES

TABLE 1 GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET SYNOPSIS, 2020-2027

TABLE 2 GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET ESTIMATES & FORECAST, 2020-2027 (USD MILLION)

TABLE 3 GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET, BY APPLICATION, 2020-2027 (USD MILLION)

TABLE 4 GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 5 GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET, BY REGION, 2020-2027 (USD MILLION)

TABLE 6 NORTH AMERICA: CARCINOEMBRYONIC ANTIGEN MARKET, BY APPLICATION, 2020-2027 (USD MILLION)

TABLE 7 NORTH AMERICA: CARCINOEMBRYONIC ANTIGEN MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 8 US: CARCINOEMBRYONIC ANTIGEN MARKET, BY APPLICATION, 2020-2027 (USD MILLION)

TABLE 9 US: CARCINOEMBRYONIC ANTIGEN MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 10 CANADA: CARCINOEMBRYONIC ANTIGEN MARKET, BY APPLICATION, 2020-2027 (USD MILLION)

TABLE 11 CANADA: CARCINOEMBRYONIC ANTIGEN MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 12 LATIN AMERICA: CARCINOEMBRYONIC ANTIGEN MARKET, BY APPLICATION, 2020-2027 (USD MILLION)

TABLE 13 LATIN AMERICA: CARCINOEMBRYONIC ANTIGEN MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 14 EUROPE: CARCINOEMBRYONIC ANTIGEN MARKET, BY APPLICATION, 2020-2027 (USD MILLION)

TABLE 15 EUROPE: CARCINOEMBRYONIC ANTIGEN MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 16 WESTERN EUROPE: CARCINOEMBRYONIC ANTIGEN MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 17 WESTERN EUROPE: CARCINOEMBRYONIC ANTIGEN MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 18 EASTERN EUROPE: CARCINOEMBRYONIC ANTIGEN MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 19 EASTERN EUROPE: CARCINOEMBRYONIC ANTIGEN MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 20 ASIA-PACIFIC: CARCINOEMBRYONIC ANTIGEN MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 21 ASIA-PACIFIC: CARCINOEMBRYONIC ANTIGEN MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 22 MIDDLE EAST & AFRICA: CARCINOEMBRYONIC ANTIGEN MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 23 MIDDLE EAST & AFRICA: CARCINOEMBRYONIC ANTIGEN MARKET, BY END USER, 2020-2027 (USD MILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE OF THE GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET
FIGURE 3 MARKET DYNAMICS OF THE GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET
FIGURE 4 GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET SHARE, BY APPLICATION, 2020 (%)
FIGURE 5 GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET SHARE, BY END USER, 2020 (%)
FIGURE 6 GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET SHARE, BY REGION, 2020 (%)
FIGURE 7 AMERICAS: CARCINOEMBRYONIC ANTIGEN MARKET SHARE BY REGION, 2020 (%)
FIGURE 8 NORTH AMERICA: CARCINOEMBRYONIC ANTIGEN MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 9 EUROPE: CARCINOEMBRYONIC ANTIGEN MARKET SHARE, BY REGION, 2020 (%)
FIGURE 10 WESTERN EUROPE: CARCINOEMBRYONIC ANTIGEN MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 11 ASIA-PACIFIC: CARCINOEMBRYONIC ANTIGEN MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 12 MIDDLE EAST & AFRICA: CARCINOEMBRYONIC ANTIGEN MARKET SHARE, BY REGION, 2020 (%)
FIGURE 13 GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET: COMPANY SHARE ANALYSIS, 2020 (%)
FIGURE 14 ABCAM PLC.: KEY FINANCIALS
FIGURE 15 ABCAM PLC: SEGMENTAL REVENUE
FIGURE 16 ABCAM PLC: REGIONAL REVENUE
FIGURE 17 BOSTER BIOLOGICAL TECHNOLOGY: KEY FINANCIALS
FIGURE 18 BOSTER BIOLOGICAL TECHNOLOGY: SEGMENTAL REVENUE
FIGURE 19 BOSTER BIOLOGICAL TECHNOLOGY: REGIONAL REVENUE
FIGURE 20 CREATIVE DIAGNOSTICS: KEY FINANCIALS
FIGURE 21 CREATIVE DIAGNOSTICS: SEGMENTAL REVENUE
FIGURE 22 CREATIVE DIAGNOSTICS: REGIONAL REVENUE
FIGURE 23 F. HOFFMANN-LA ROCHE LTD: KEY FINANCIALS
FIGURE 24 F. HOFFMANN-LA ROCHE LTD: SEGMENTAL REVENUE
FIGURE 25 F. HOFFMANN-LA ROCHE LTD: REGIONAL REVENUE
FIGURE 26 GENWAY BIOTECH, INC.: KEY FINANCIALS
FIGURE 27 GENWAY BIOTECH, INC.: SEGMENTAL REVENUE
FIGURE 28 GENWAY BIOTECH, INC.: REGIONAL REVENUE
FIGURE 29 LABORATORY CORPORATION OF AMERICA HOLDINGS: KEY FINANCIALS
FIGURE 30 LABORATORY CORPORATION OF AMERICA HOLDINGS: SEGMENTAL REVENUE
FIGURE 31 LABORATORY CORPORATION OF AMERICA HOLDINGS: REGIONAL REVENUE
FIGURE 32 LEE BIOSOLUTIONS: KEY FINANCIALS
FIGURE 33 LEE BIOSOLUTIONS: SEGMENTAL REVENUE
FIGURE 34 LEE BIOSOLUTIONS: REGIONAL REVENUE
FIGURE 35 MERCK KGAA: KEY FINANCIALS
FIGURE 36 MERCK KGAA: SEGMENTAL REVENUE
FIGURE 37 MERCK KGAA: REGIONAL REVENUE
FIGURE 38 QUEST DIAGNOSTICS INCORPORATED: KEY FINANCIALS
FIGURE 39 QUEST DIAGNOSTICS INCORPORATED: SEGMENTAL REVENUE
FIGURE 40 QUEST DIAGNOSTICS INCORPORATED: REGIONAL REVENUE
FIGURE 41 RAYBIOTECH, INC.: KEY FINANCIALS
FIGURE 42 RAYBIOTECH, INC.: SEGMENTAL REVENUE
FIGURE 43 RAYBIOTECH, INC.: REGIONAL REVENUE